{
  "symbol": "ABBV",
  "year": 2025,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2748,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.084
  },
  "top_positive": [
    {
      "sent": "The following table details AbbVie\u2019s worldwide net revenues: Three months ended June 30, Six months ended June 30, (in\u00a0millions) 2025 2024 2025 2024 Immunology Skyrizi United States $ 3,843 $ 2,340 $ 6,762 $ 3,996 International 580 387 1,086 739 Total $ 4,423 $ 2,727 $ 7,848 $ 4,735 Rinvoq United States $ 1,452 $ 1,017 $ 2,672 $ 1,742 International 576 413 1,074 781 Total $ 2,028 $ 1,430 $ 3,746 $ 2,523 Humira United States $ 802 $ 2,360 $ 1,546 $ 4,131 International 378 454 755 953 Total $ 1,180 $ 2,814 $ 2,301 $ 5,084 Neuroscience Vraylar United States $ 898 $ 773 $ 1,661 $ 1,465 International 2 1 4 3 Total $ 900 $ 774 $ 1,665 $ 1,468 Botox Therapeutic United States $ 775 $ 669 $ 1,498 $ 1,280 International 153 145 296 282 Total $ 928 $ 814 $ 1,794 $ 1,562 Ubrelvy United States $ 330 $ 227 $ 563 $ 424 International 8 4 15 10 Total $ 338 $ 231 $ 578 $ 434 Qulipta United States $ 237 $ 146 $ 409 $ 274 International 30 4 51 7 Total $ 267 $ 150 $ 460 $ 281 Vyalev United States $ 22 $ \u2014 $ 28 $ \u2014 International 76 18 133 27 Total $ 98 $ 18 $ 161 $ 27 Duodopa United States $ 20 $ 23 $ 40 $ 48 International 77 90 153 180 Total $ 97 $ 113 $ 193 $ 228 Other Neuroscience United States $ 51 $ 57 $ 106 $ 118 International 4 5 8 9 Total $ 55 $ 62 $ 114 $ 127 2025 Form 10-Q | 25 Three months ended June 30, Six months ended June 30, (in\u00a0millions) 2025 2024 2025 2024 Oncology Imbruvica United States $ 543 $ 595 $ 1,072 $ 1,205 Collaboration revenues 211 238 420 466 Total $ 754 $ 833 $ 1,492 $ 1,671 Venclexta United States $ 321 $ 300 $ 633 $ 581 International 370 337 723 670 Total $ 691 $ 637 $ 1,356 $ 1,251 Elahere United States $ 138 $ 128 $ 303 $ 192 International 21 \u2014 35 \u2014 Total $ 159 $ 128 $ 338 $ 192 Epkinly Collaboration revenues $ 49 $ 29 $ 85 $ 51 International 21 7 36 12 Total $ 70 $ 36 $ 121 $ 63 Other Oncology United States $ 2 $ \u2014 $ 2 $ \u2014 Aesthetics Botox Cosmetic United States $ 410 $ 450 $ 705 $ 839 International 282 279 543 523 Total $ 692 $ 729 $ 1,248 $ 1,362 Juvederm Collection United States $ 105 $ 138 $ 180 $ 244 International 155 205 311 396 Total $ 260 $ 343 $ 491 $ 640 Other Aesthetics United States $ 282 $ 275 $ 552 $ 556 International 45 43 90 81 Total $ 327 $ 318 $ 642 $ 637 Eye Care Ozurdex United States $ 30 $ 35 $ 60 $ 69 International 95 89 188 186 Total $ 125 $ 124 $ 248 $ 255 Lumigan/Ganfort United States $ 52 $ 42 $ 100 $ 71 International 51 61 109 123 Total $ 103 $ 103 $ 209 $ 194 Alphagan/Combigan United States $ \u2014 $ 13 $ 26 $ 28 International 36 36 70 80 Total $ 36 $ 49 $ 96 $ 108 Other Eye Care United States $ 144 $ 149 $ 261 $ 298 International 106 108 206 216 Total $ 250 $ 257 $ 467 $ 514 Other Key Products Mavyret United States $ 184 $ 167 $ 326 $ 311 International 191 202 355 407 Total $ 375 $ 369 $ 681 $ 718 Creon United States $ 404 $ 372 $ 759 $ 657 Linzess/Constella United States $ 247 $ 211 $ 386 $ 468 International 11 10 20 19 Total $ 258 $ 221 $ 406 $ 487 All other $ 603 $ 810 $ 1,350 $ 1,554 Total net revenues $ 15,423 $ 14,462 $ 28,766 $ 26,772 See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), change in fair value of contingent consideration (Note 8), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 12), income tax expense (Note 11) and restructuring expense (Note 7).",
      "score": 0.9974
    },
    {
      "sent": "Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 2025 2024 United States $ 11,762 $ 11,106 5.9 % 5.9 % $ 21,741 $ 20,147 7.9 % 7.9 % International 3,661 3,356 9.1 % 8.4 % 7,025 6,625 6.0 % 8.3 % Net revenues $ 15,423 $ 14,462 6.6 % 6.5 % $ 28,766 $ 26,772 7.4 % 8.0 % 2025 Form 10-Q | 30 The following table details AbbVie\u2019s worldwide net revenues: Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 2025 2024 Immunology Skyrizi United States $ 3,843 $ 2,340 64.3 % 64.3 % $ 6,762 $ 3,996 69.2 % 69.2 % International 580 387 49.7 % 47.2 % 1,086 739 46.9 % 49.6 % Total $ 4,423 $ 2,727 62.2 % 61.8 % $ 7,848 $ 4,735 65.8 % 66.2 % Rinvoq United States $ 1,452 $ 1,017 42.7 % 42.7 % $ 2,672 $ 1,742 53.3 % 53.3 % International 576 413 39.6 % 37.5 % 1,074 781 37.6 % 40.1 % Total $ 2,028 $ 1,430 41.8 % 41.2 % $ 3,746 $ 2,523 48.5 % 49.3 % Humira United States $ 802 $ 2,360 (66.0) % (66.0) % $ 1,546 $ 4,131 (62.6) % (62.6) % International 378 454 (16.8) % (17.2) % 755 953 (20.8) % (18.4) % Total $ 1,180 $ 2,814 (58.1) % (58.2) % $ 2,301 $ 5,084 (54.7) % (54.3) % Neuroscience Vraylar United States $ 898 $ 773 16.2 % 16.2 % $ 1,661 $ 1,465 13.4 % 13.4 % International 2 1 72.8 % 76.8 % 4 3 41.8 % 47.4 % Total $ 900 $ 774 16.3 % 16.3 % $ 1,665 $ 1,468 13.5 % 13.5 % Botox Therapeutic United States $ 775 $ 669 15.9 % 15.9 % $ 1,498 $ 1,280 17.0 % 17.0 % International 153 145 5.7 % 6.0 % 296 282 5.2 % 8.6 % Total $ 928 $ 814 14.1 % 14.2 % $ 1,794 $ 1,562 14.9 % 15.5 % Ubrelvy United States $ 330 $ 227 46.5 % 46.5 % $ 563 $ 424 33.0 % 33.0 % International 8 4 73.9 % 76.7 % 15 10 46.7 % 51.2 % Total $ 338 $ 231 47.1 % 47.2 % $ 578 $ 434 33.3 % 33.4 % Qulipta United States $ 237 $ 146 62.8 % 62.8 % $ 409 $ 274 49.5 % 49.5 % International 30 4 >100.0 % >100.0 % 51 7 >100.0 % >100.0 % Total $ 267 $ 150 77.5 % 76.9 % $ 460 $ 281 63.6 % 63.6 % Vyalev United States $ 22 $ \u2014 n/m n/m $ 28 $ \u2014 n/m n/m International 76 18 >100.0 % >100.0 % 133 27 >100.0 % >100.0 % Total $ 98 $ 18 >100.0 % >100.0 % $ 161 $ 27 >100.0 % >100.0 % Duodopa United States $ 20 $ 23 (13.6) % (13.6) % $ 40 $ 48 (16.6) % (16.6) % International 77 90 (13.7) % (16.3) % 153 180 (14.9) % (14.0) % Total $ 97 $ 113 (13.7) % (15.7) % $ 193 $ 228 (15.2) % (14.5) % Other Neuroscience United States $ 51 $ 57 (11.4) % (11.4) % $ 106 $ 118 (10.4) % (10.4) % International 4 5 (23.3) % (21.3) % 8 9 (12.7) % (8.1) % Total $ 55 $ 62 (12.3) % (12.2) % $ 114 $ 127 (10.5) % (10.2) % Oncology Imbruvica United States $ 543 $ 595 (8.9) % (8.9) % $ 1,072 $ 1,205 (11.1) % (11.1) % Collaboration revenues 211 238 (11.2) % (11.2) % 420 466 (9.7) % (9.7) % Total $ 754 $ 833 (9.5) % (9.5) % $ 1,492 $ 1,671 (10.7) % (10.7) % Venclexta United States $ 321 $ 300 7.4 % 7.4 % $ 633 $ 581 9.1 % 9.1 % International 370 337 9.5 % 9.1 % 723 670 7.8 % 11.3 % Total $ 691 $ 637 8.5 % 8.3 % $ 1,356 $ 1,251 8.4 % 10.3 % Elahere United States $ 138 $ 128 8.0 % 8.0 % $ 303 $ 192 57.5 % 57.5 % International 21 \u2014 n/m n/m 35 \u2014 n/m n/m Total $ 159 $ 128 24.2 % 23.7 % $ 338 $ 192 75.5 % 75.5 % Epkinly Collaboration revenues $ 49 $ 29 70.5 % 70.5 % $ 85 $ 51 66.8 % 66.8 % International 21 7 >100.0 % >100.0 % 36 12 >100.0 % >100.0 % Total $ 70 $ 36 93.9 % 92.3 % $ 121 $ 63 92.1 % 93.3 % Other Oncology United States $ 2 $ \u2014 n/m n/m $ 2 $ \u2014 n/m n/m Aesthetics Botox Cosmetic United States $ 410 $ 450 (8.7) % (8.7) % $ 705 $ 839 (15.9) % (15.9) % International 282 279 0.9 % 1.2 % 543 523 3.7 % 5.8 % Total $ 692 $ 729 (5.0) % (4.9) % $ 1,248 $ 1,362 (8.4) % (7.6) % 2025 Form 10-Q | 31 Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 2025 2024 Juvederm Collection United States $ 105 $ 138 (23.6) % (23.6) % $ 180 $ 244 (25.9) % (25.9) % International 155 205 (24.4) % (24.4) % 311 396 (21.5) % (19.8) % Total $ 260 $ 343 (24.0) % (24.0) % $ 491 $ 640 (23.2) % (22.2) % Other Aesthetics United States $ 282 $ 275 1.6 % 1.6 % $ 552 $ 556 (1.0) % (1.0) % International 45 43 5.8 % 6.4 % 90 81 11.7 % 14.5 % Total $ 327 $ 318 2.2 % 2.3 % $ 642 $ 637 0.6 % 0.9 % Eye Care Ozurdex United States $ 30 $ 35 (12.6) % (12.6) % $ 60 $ 69 (12.4) % (12.4) % International 95 89 5.8 % 4.4 % 188 186 0.8 % 2.7 % Total $ 125 $ 124 0.6 % (0.4) % $ 248 $ 255 (2.8) % (1.4) % Lumigan/Ganfort United States $ 52 $ 42 19.9 % 19.9 % $ 100 $ 71 39.4 % 39.4 % International 51 61 (15.4) % (15.2) % 109 123 (11.0) % (7.7) % Total $ 103 $ 103 (0.8) % (0.7) % $ 209 $ 194 7.5 % 9.6 % Alphagan/Combigan United States $ \u2014 $ 13 (91.6) % (91.6) % $ 26 $ 28 (3.6) % (3.6) % International 36 36 (3.1) % (0.2) % 70 80 (13.1) % (8.5) % Total $ 36 $ 49 (25.6) % (23.5) % $ 96 $ 108 (10.6) % (7.2) % Other Eye Care United States $ 144 $ 149 (4.3) % (4.3) % $ 261 $ 298 (12.8) % (12.8) % International 106 108 (1.7) % 0.9 % 206 216 (4.4) % 0.3 % Total $ 250 $ 257 (3.2) % (2.1) % $ 467 $ 514 (9.3) % (7.3) % Other Key Products Mavyret United States $ 184 $ 167 9.7 % 9.7 % $ 326 $ 311 4.9 % 4.9 % International 191 202 (5.1) % (6.5) % 355 407 (12.8) % (11.2) % Total $ 375 $ 369 1.6 % 0.8 % $ 681 $ 718 (5.1) % (4.2) % Creon United States $ 404 $ 372 8.4 % 8.4 % $ 759 $ 657 15.4 % 15.4 % Linzess/Constella United States $ 247 $ 211 17.4 % 17.4 % $ 386 $ 468 (17.4) % (17.4) % International 11 10 10.8 % 10.3 % 20 19 7.0 % 9.7 % Total $ 258 $ 221 17.1 % 17.1 % $ 406 $ 487 (16.5) % (16.4) % All other $ 603 $ 810 (25.4) % (24.8) % $ 1,350 $ 1,554 (13.1) % (12.5) % Total net revenues $ 15,423 $ 14,462 6.6 % 6.5 % $ 28,766 $ 26,772 7.4 % 8.0 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis.",
      "score": 0.9968
    },
    {
      "sent": "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, neuroscience, oncology, aesthetics and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt.",
      "score": 0.986
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.",
      "score": -0.7506
    },
    {
      "sent": "AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud.",
      "score": -0.7269
    }
  ],
  "forward_snippets": [
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "Cerevel Therapeutics neuroscience pipeline included multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders.",
    "ImmunoGen's oncology portfolio included its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors.",
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements."
  ],
  "curated_text": "Symbol: ABBV. Year: 2025. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: The following table details AbbVie\u2019s worldwide net revenues: Three months ended June 30, Six months ended June 30, (in\u00a0millions) 2025 2024 2025 2024 Immunology Skyrizi United States $ 3,843 $ 2,340 $ 6,762 $ 3,996 International 580 387 1,086 739 Total $ 4,423 $ 2,727 $ 7,848 $ 4,735 Rinvoq United States $ 1,452 $ 1,017 $ 2,672 $ 1,742 International 576 413 1,074 781 Total $ 2,028 $ 1,430 $ 3,746 $ 2,523 Humira United States $ 802 $ 2,360 $ 1,546 $ 4,131 International 378 454 755 953 Total $ 1,180 $ 2,814 $ 2,301 $ 5,084 Neuroscience Vraylar United States $ 898 $ 773 $ 1,661 $ 1,465 International 2 1 4 3 Total $ 900 $ 774 $ 1,665 $ 1,468 Botox Therapeutic United States $ 775 $ 669 $ 1,498 $ 1,280 International 153 145 296 282 Total $ 928 $ 814 $ 1,794 $ 1,562 Ubrelvy United States $ 330 $ 227 $ 563 $ 424 International 8 4 15 10 Total $ 338 $ 231 $ 578 $ 434 Qulipta United States $ 237 $ 146 $ 409 $ 274 International 30 4 51 7 Total $ 267 $ 150 $ 460 $ 281 Vyalev United States $ 22 $ \u2014 $ 28 $ \u2014 International 76 18 133 27 Total $ 98 $ 18 $ 161 $ 27 Duodopa United States $ 20 $ 23 $ 40 $ 48 International 77 90 153 180 Total $ 97 $ 113 $ 193 $ 228 Other Neuroscience United States $ 51 $ 57 $ 106 $ 118 International 4 5 8 9 Total $ 55 $ 62 $ 114 $ 127 2025 Form 10-Q | 25 Three months ended June 30, Six months ended June 30, (in\u00a0millions) 2025 2024 2025 2024 Oncology Imbruvica United States $ 543 $ 595 $ 1,072 $ 1,205 Collaboration revenues 211 238 420 466 Total $ 754 $ 833 $ 1,492 $ 1,671 Venclexta United States $ 321 $ 300 $ 633 $ 581 International 370 337 723 670 Total $ 691 $ 637 $ 1,356 $ 1,251 Elahere United States $ 138 $ 128 $ 303 $ 192 International 21 \u2014 35 \u2014 Total $ 159 $ 128 $ 338 $ 192 Epkinly Collaboration revenues $ 49 $ 29 $ 85 $ 51 International 21 7 36 12 Total $ 70 $ 36 $ 121 $ 63 Other Oncology United States $ 2 $ \u2014 $ 2 $ \u2014 Aesthetics Botox Cosmetic United States $ 410 $ 450 $ 705 $ 839 International 282 279 543 523 Total $ 692 $ 729 $ 1,248 $ 1,362 Juvederm Collection United States $ 105 $ 138 $ 180 $ 244 International 155 205 311 396 Total $ 260 $ 343 $ 491 $ 640 Other Aesthetics United States $ 282 $ 275 $ 552 $ 556 International 45 43 90 81 Total $ 327 $ 318 $ 642 $ 637 Eye Care Ozurdex United States $ 30 $ 35 $ 60 $ 69 International 95 89 188 186 Total $ 125 $ 124 $ 248 $ 255 Lumigan/Ganfort United States $ 52 $ 42 $ 100 $ 71 International 51 61 109 123 Total $ 103 $ 103 $ 209 $ 194 Alphagan/Combigan United States $ \u2014 $ 13 $ 26 $ 28 International 36 36 70 80 Total $ 36 $ 49 $ 96 $ 108 Other Eye Care United States $ 144 $ 149 $ 261 $ 298 International 106 108 206 216 Total $ 250 $ 257 $ 467 $ 514 Other Key Products Mavyret United States $ 184 $ 167 $ 326 $ 311 International 191 202 355 407 Total $ 375 $ 369 $ 681 $ 718 Creon United States $ 404 $ 372 $ 759 $ 657 Linzess/Constella United States $ 247 $ 211 $ 386 $ 468 International 11 10 20 19 Total $ 258 $ 221 $ 406 $ 487 All other $ 603 $ 810 $ 1,350 $ 1,554 Total net revenues $ 15,423 $ 14,462 $ 28,766 $ 26,772 See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), change in fair value of contingent consideration (Note 8), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 12), income tax expense (Note 11) and restructuring expense (Note 7). Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 2025 2024 United States $ 11,762 $ 11,106 5.9 % 5.9 % $ 21,741 $ 20,147 7.9 % 7.9 % International 3,661 3,356 9.1 % 8.4 % 7,025 6,625 6.0 % 8.3 % Net revenues $ 15,423 $ 14,462 6.6 % 6.5 % $ 28,766 $ 26,772 7.4 % 8.0 % 2025 Form 10-Q | 30 The following table details AbbVie\u2019s worldwide net revenues: Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 2025 2024 Immunology Skyrizi United States $ 3,843 $ 2,340 64.3 % 64.3 % $ 6,762 $ 3,996 69.2 % 69.2 % International 580 387 49.7 % 47.2 % 1,086 739 46.9 % 49.6 % Total $ 4,423 $ 2,727 62.2 % 61.8 % $ 7,848 $ 4,735 65.8 % 66.2 % Rinvoq United States $ 1,452 $ 1,017 42.7 % 42.7 % $ 2,672 $ 1,742 53.3 % 53.3 % International 576 413 39.6 % 37.5 % 1,074 781 37.6 % 40.1 % Total $ 2,028 $ 1,430 41.8 % 41.2 % $ 3,746 $ 2,523 48.5 % 49.3 % Humira United States $ 802 $ 2,360 (66.0) % (66.0) % $ 1,546 $ 4,131 (62.6) % (62.6) % International 378 454 (16.8) % (17.2) % 755 953 (20.8) % (18.4) % Total $ 1,180 $ 2,814 (58.1) % (58.2) % $ 2,301 $ 5,084 (54.7) % (54.3) % Neuroscience Vraylar United States $ 898 $ 773 16.2 % 16.2 % $ 1,661 $ 1,465 13.4 % 13.4 % International 2 1 72.8 % 76.8 % 4 3 41.8 % 47.4 % Total $ 900 $ 774 16.3 % 16.3 % $ 1,665 $ 1,468 13.5 % 13.5 % Botox Therapeutic United States $ 775 $ 669 15.9 % 15.9 % $ 1,498 $ 1,280 17.0 % 17.0 % International 153 145 5.7 % 6.0 % 296 282 5.2 % 8.6 % Total $ 928 $ 814 14.1 % 14.2 % $ 1,794 $ 1,562 14.9 % 15.5 % Ubrelvy United States $ 330 $ 227 46.5 % 46.5 % $ 563 $ 424 33.0 % 33.0 % International 8 4 73.9 % 76.7 % 15 10 46.7 % 51.2 % Total $ 338 $ 231 47.1 % 47.2 % $ 578 $ 434 33.3 % 33.4 % Qulipta United States $ 237 $ 146 62.8 % 62.8 % $ 409 $ 274 49.5 % 49.5 % International 30 4 >100.0 % >100.0 % 51 7 >100.0 % >100.0 % Total $ 267 $ 150 77.5 % 76.9 % $ 460 $ 281 63.6 % 63.6 % Vyalev United States $ 22 $ \u2014 n/m n/m $ 28 $ \u2014 n/m n/m International 76 18 >100.0 % >100.0 % 133 27 >100.0 % >100.0 % Total $ 98 $ 18 >100.0 % >100.0 % $ 161 $ 27 >100.0 % >100.0 % Duodopa United States $ 20 $ 23 (13.6) % (13.6) % $ 40 $ 48 (16.6) % (16.6) % International 77 90 (13.7) % (16.3) % 153 180 (14.9) % (14.0) % Total $ 97 $ 113 (13.7) % (15.7) % $ 193 $ 228 (15.2) % (14.5) % Other Neuroscience United States $ 51 $ 57 (11.4) % (11.4) % $ 106 $ 118 (10.4) % (10.4) % International 4 5 (23.3) % (21.3) % 8 9 (12.7) % (8.1) % Total $ 55 $ 62 (12.3) % (12.2) % $ 114 $ 127 (10.5) % (10.2) % Oncology Imbruvica United States $ 543 $ 595 (8.9) % (8.9) % $ 1,072 $ 1,205 (11.1) % (11.1) % Collaboration revenues 211 238 (11.2) % (11.2) % 420 466 (9.7) % (9.7) % Total $ 754 $ 833 (9.5) % (9.5) % $ 1,492 $ 1,671 (10.7) % (10.7) % Venclexta United States $ 321 $ 300 7.4 % 7.4 % $ 633 $ 581 9.1 % 9.1 % International 370 337 9.5 % 9.1 % 723 670 7.8 % 11.3 % Total $ 691 $ 637 8.5 % 8.3 % $ 1,356 $ 1,251 8.4 % 10.3 % Elahere United States $ 138 $ 128 8.0 % 8.0 % $ 303 $ 192 57.5 % 57.5 % International 21 \u2014 n/m n/m 35 \u2014 n/m n/m Total $ 159 $ 128 24.2 % 23.7 % $ 338 $ 192 75.5 % 75.5 % Epkinly Collaboration revenues $ 49 $ 29 70.5 % 70.5 % $ 85 $ 51 66.8 % 66.8 % International 21 7 >100.0 % >100.0 % 36 12 >100.0 % >100.0 % Total $ 70 $ 36 93.9 % 92.3 % $ 121 $ 63 92.1 % 93.3 % Other Oncology United States $ 2 $ \u2014 n/m n/m $ 2 $ \u2014 n/m n/m Aesthetics Botox Cosmetic United States $ 410 $ 450 (8.7) % (8.7) % $ 705 $ 839 (15.9) % (15.9) % International 282 279 0.9 % 1.2 % 543 523 3.7 % 5.8 % Total $ 692 $ 729 (5.0) % (4.9) % $ 1,248 $ 1,362 (8.4) % (7.6) % 2025 Form 10-Q | 31 Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 2025 2024 Juvederm Collection United States $ 105 $ 138 (23.6) % (23.6) % $ 180 $ 244 (25.9) % (25.9) % International 155 205 (24.4) % (24.4) % 311 396 (21.5) % (19.8) % Total $ 260 $ 343 (24.0) % (24.0) % $ 491 $ 640 (23.2) % (22.2) % Other Aesthetics United States $ 282 $ 275 1.6 % 1.6 % $ 552 $ 556 (1.0) % (1.0) % International 45 43 5.8 % 6.4 % 90 81 11.7 % 14.5 % Total $ 327 $ 318 2.2 % 2.3 % $ 642 $ 637 0.6 % 0.9 % Eye Care Ozurdex United States $ 30 $ 35 (12.6) % (12.6) % $ 60 $ 69 (12.4) % (12.4) % International 95 89 5.8 % 4.4 % 188 186 0.8 % 2.7 % Total $ 125 $ 124 0.6 % (0.4) % $ 248 $ 255 (2.8) % (1.4) % Lumigan/Ganfort United States $ 52 $ 42 19.9 % 19.9 % $ 100 $ 71 39.4 % 39.4 % International 51 61 (15.4) % (15.2) % 109 123 (11.0) % (7.7) % Total $ 103 $ 103 (0.8) % (0.7) % $ 209 $ 194 7.5 % 9.6 % Alphagan/Combigan United States $ \u2014 $ 13 (91.6) % (91.6) % $ 26 $ 28 (3.6) % (3.6) % International 36 36 (3.1) % (0.2) % 70 80 (13.1) % (8.5) % Total $ 36 $ 49 (25.6) % (23.5) % $ 96 $ 108 (10.6) % (7.2) % Other Eye Care United States $ 144 $ 149 (4.3) % (4.3) % $ 261 $ 298 (12.8) % (12.8) % International 106 108 (1.7) % 0.9 % 206 216 (4.4) % 0.3 % Total $ 250 $ 257 (3.2) % (2.1) % $ 467 $ 514 (9.3) % (7.3) % Other Key Products Mavyret United States $ 184 $ 167 9.7 % 9.7 % $ 326 $ 311 4.9 % 4.9 % International 191 202 (5.1) % (6.5) % 355 407 (12.8) % (11.2) % Total $ 375 $ 369 1.6 % 0.8 % $ 681 $ 718 (5.1) % (4.2) % Creon United States $ 404 $ 372 8.4 % 8.4 % $ 759 $ 657 15.4 % 15.4 % Linzess/Constella United States $ 247 $ 211 17.4 % 17.4 % $ 386 $ 468 (17.4) % (17.4) % International 11 10 10.8 % 10.3 % 20 19 7.0 % 9.7 % Total $ 258 $ 221 17.1 % 17.1 % $ 406 $ 487 (16.5) % (16.4) % All other $ 603 $ 810 (25.4) % (24.8) % $ 1,350 $ 1,554 (13.1) % (12.5) % Total net revenues $ 15,423 $ 14,462 6.6 % 6.5 % $ 28,766 $ 26,772 7.4 % 8.0 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis. AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, neuroscience, oncology, aesthetics and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt. Top negative sentences: Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. Forward-looking snippets: AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. Cerevel Therapeutics neuroscience pipeline included multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders. ImmunoGen's oncology portfolio included its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements."
}